The phase III IMmotion151 trial found that the combination of atezolizumab and bevacizumab boosts progression-free survival compared with sunitinib in patients with advanced or metastatic renal cell carcinoma. The increase was 2.8 months in all patients and 3.5 months in patients with PD-L1–positive tumors.
from #ORL-AlexandrosSfakianakis via ola Kala on Inoreader https://ift.tt/2pZdjDZ
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου